| Introduction | For Patients | For Science | For Society | Looking Ahead How Innovation Becomes Patient Impact CSL combines world-leading science, specialist manufacturing, strategic partnerships and clinical expertise to transform promising discoveries into novel therapies. By maintaining a balanced portfolio of research – both advancing existing medicines and investing in the next generation of treatments – we continue to build a pipeline designed to meet patient needs and priorities today, while preparing for the healthcare challenges of tomorrow. Priority Why It Matters Address unmet medical needs Focus on diseases where patients have limited treatment options. Advance differentiated therapies Develop medicines that combine scientific innovation with specialised manufacturing expertise. Strengthen our therapeutic leadership Build on CSL's expertise in immunology, haematology, cardiovascular and renal disease, transplantation and vaccines. Accelerate the path from discovery to patients Integrate research, partnerships, portfolio development and commercialisation. Invest in next-generation technologies Harness advanced biologics, AI and digital capabilities to improve research and manufacturing. Build innovation for the future Develop global research capability, manufacturing excellence and strategic partnerships that sustain long-term patient impact. By partnering with biotech’s brightest, we continually renew our therapeutic portfolio with the most promising scientific advances. Pairing their breakthroughs with our deep disease, operations and commercial expertise will ultimately allow accelerated development of transformative therapies for patients with rare and serious diseases. Gordon Naylor, CSL's Interim Chief Executive Officer and Managing Director Investing in the Future of Medicine clinical trials in operation across all therapeutic areas 23 new indications for existing products 60 new product registrations 83 major regulatory approvals $1.2b USD invested in R&D 41 Our Innovation Priorities 22 | CSL IMPACT REPORT 2026
RkJQdWJsaXNoZXIy MjE2NDg3